These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 16489048

  • 21. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
    Saha A, Chatterjee SK, Foon KA, Primus FJ, Sreedharan S, Mohanty K, Bhattacharya-Chatterjee M.
    Cancer Res; 2004 Jul 15; 64(14):4995-5003. PubMed ID: 15256474
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
    Krishnan L, Sad S, Patel GB, Sprott GD.
    Cancer Res; 2003 May 15; 63(10):2526-34. PubMed ID: 12750276
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
    Preynat-Seauve O, Contassot E, Schuler P, French LE, Huard B.
    Melanoma Res; 2007 Jun 15; 17(3):169-76. PubMed ID: 17505262
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Enhanced translational efficacy of internal ribosomal entry site-mediated mRNA in dendritic cells contributes to efficient induction of antitumor immunity].
    Tan XH, Wan YH.
    Zhonghua Yi Xue Za Zhi; 2007 Feb 06; 87(6):399-403. PubMed ID: 17456382
    [Abstract] [Full Text] [Related]

  • 28. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y, Ikuta Y, Kuronuma T, Komori H, Ito M, Tsuchihara M, Tsunoda Y, Shirakawa H, Baba H, Nishimura Y, Kinoshita T, Nakatsura T.
    Int J Oncol; 2008 May 06; 32(5):985-90. PubMed ID: 18425324
    [Abstract] [Full Text] [Related]

  • 29. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
    Pilon-Thomas S, Li W, Briggs JJ, Djeu J, Mulé JJ, Riker AI.
    J Immunother; 2006 May 06; 29(4):381-7. PubMed ID: 16799333
    [Abstract] [Full Text] [Related]

  • 30. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
    Machlenkin A, Goldberger O, Tirosh B, Paz A, Volovitz I, Bar-Haim E, Lee SH, Vadai E, Tzehoval E, Eisenbach L.
    Clin Cancer Res; 2005 Jul 01; 11(13):4955-61. PubMed ID: 16000595
    [Abstract] [Full Text] [Related]

  • 31. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination.
    Matsuyoshi H, Senju S, Hirata S, Yoshitake Y, Uemura Y, Nishimura Y.
    J Immunol; 2004 Jan 15; 172(2):776-86. PubMed ID: 14707047
    [Abstract] [Full Text] [Related]

  • 32. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
    Hao S, Bai O, Yuan J, Qureshi M, Xiang J.
    Cell Mol Immunol; 2006 Jun 15; 3(3):205-11. PubMed ID: 16893501
    [Abstract] [Full Text] [Related]

  • 33. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
    Steitz J, Brück J, Lenz J, Knop J, Tüting T.
    Cancer Res; 2001 Dec 15; 61(24):8643-6. PubMed ID: 11751377
    [Abstract] [Full Text] [Related]

  • 34. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.
    Shimizu K, Fields RC, Redman BG, Giedlin M, Mulé JJ.
    Cancer J Sci Am; 2000 Feb 15; 6 Suppl 1():S67-75. PubMed ID: 10685663
    [Abstract] [Full Text] [Related]

  • 35. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice.
    Asada H, Kishida T, Hirai H, Shin-Ya M, Imanishi J, Takeuchi M, Mazda O.
    Cancer Lett; 2006 Aug 18; 240(1):83-93. PubMed ID: 16246489
    [Abstract] [Full Text] [Related]

  • 36. [Feasibility of using hepatitis B virus surface antigen as target antigen in immunogen therapy against cancer].
    Qiu S, Ye S, Tang Z, Qian S, Li L.
    Zhonghua Yi Xue Za Zhi; 2002 Feb 25; 82(4):253-6. PubMed ID: 11953174
    [Abstract] [Full Text] [Related]

  • 37. Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma.
    O-Sullivan I, Kim TS, Chopra A, Cohen EP.
    Anticancer Res; 2006 Feb 25; 26(2A):873-84. PubMed ID: 16619482
    [Abstract] [Full Text] [Related]

  • 38. Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells.
    Senju S, Haruta M, Matsunaga Y, Fukushima S, Ikeda T, Takahashi K, Okita K, Yamanaka S, Nishimura Y.
    Stem Cells; 2009 May 25; 27(5):1021-31. PubMed ID: 19415766
    [Abstract] [Full Text] [Related]

  • 39. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma.
    Shibagaki N, Udey MC.
    Eur J Immunol; 2003 Apr 25; 33(4):850-60. PubMed ID: 12672050
    [Abstract] [Full Text] [Related]

  • 40. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M, Andarini S, Zaini J, Xin H, Kanehira M, Suzuki T, Fukuhara T, Mizuguchi H, Hayakawa T, Saijo Y, Nukiwa T, Kikuchi T.
    Eur J Immunol; 2006 Apr 25; 36(4):1019-27. PubMed ID: 16525992
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.